Abstract: Objective The aim of this study was to evaluate the clinical efficacy and hematologic toxicity of docetaxel in the treatment of metastatic breast cancer patients in different age groups.Methods The clinical data of three groups of single-agent docetaxel in the treatment of metastatic breast cancer patients were retrospectively analyzed.The clinical efficacy of docetaxel was analyzed statistically.Results The Objective response rate(ORR)and clinical beneficial rate(CBR)in the group of age＜=45 year group were 30.6% and 38.7%,and the ORR and CBR in the 46~59 age were 27.5% and 35.7%,while ORR and CBR in the ≥60 age group were 20.0% and 27.5%.The median progress free survival(PFS)in three groups was 6.0(2.9~9.1)months,5.0(2.9~7.1)months and 4.0(3.3~4.7)months,respectively.There was no statistical difference in three different age groups(P=0.477,0.492 and 0.460,respectively).Cox regression analysis showed that the docetaxel rescue treatment of PFS had not associated with clinical stage,pathological type,ipsilateral axillary lymph node metastasis,disease free survival,unit dose of body surface area dose,number of rescue treatment lines,number of recurrence and metastasis,etc.in three different age groups of patients with metastatic breast cancer.Hematological toxicity was mainly manifested by a decrease in white blood cells and neutrophils,and docetaxel has less effect on hemoglobin and platelets.Conclusion The clinical efficacy and hematologic toxicity of docetaxel have a certain degree of correlation with ages.With the increase of age,the clinical curative effect is reduced and the blood toxicity is aggravated.

Key words: Different age groups, Metastatic breast cancer, Docetaxel, Clinical effects